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Abstract
Cyclam was attached to 1-, 2- and 3-pyrrole lexitropsins for the first time through a synthetically facile copper-catalyzed
‘‘click’’ reaction. The corresponding copper and zinc complexes were synthesized and characterized. The ligand and its
complexes bound AT-rich DNA selectively over GC-rich DNA, and the thermodynamic profile of the binding was evaluated
by isothermal titration calorimetry. The metal, encapsulated in a scorpion azamacrocyclic complex, did not affect the
binding, which was dominated by the organic tail.
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Introduction
The sequence-selective binding of small molecules to DNA is an
important area of research because through such binding it may
be possible to control gene expression, which has significant
implications for new therapeutics.[1–5] Small molecule-based
metal complexes are particularly sought-after in this regard since
DNA binding may be used to trigger reactivity, unleashing
chemical activity at a specific sequence of genetic information that
is associated with disease.[6–7]
Many naturally-occurring small molecules are known to bind
DNA with sequence selectivity, most notably the polyamide class of
minor groove binders that includes distamycin and netropsin,
known generically as the lexitropsins.[8–12] Distamycin and
netropsin selectively bind AT-rich regions of DNA, sequences that
are important for example because of the widespread occurrence of
the TATA box transcription factor binding site in the genome.[13]
Lexitropsins are structurally simple molecules possessing features
that are well-suited for minor groove binding: they are curved
(although this is not an absolute requirement[14]), flat and contain
well-positioned hydrogen bonding groups, positively charged end
groups and strategically placed van der Waals contacts.[15–16]
With such a well-evolved scaffold for interaction with DNA, it is
unsurprising that there has been a great deal of interest in tailoring
the basic design to build in greater sequence-selectivity and adapt
these structures to develop new types of drugs.[17–36] Much has
been learned about how to modify lexitropsin structures to achieve
binding to bespoke DNA sequences[9,37–42] or to improve
physicochemical and pharmacokinetic properties.[26,43–47]
There has been much interest in the attachment of chemically
active groups such as alkylating agents to lexitropsins in the hope
of targeting reactive chemical functionality to the double
helix.[48–49] Given the potential of metal-based artificial
nucleases and imaging agents, it is surprising that only a relatively
small number of lexitropsin-metal conjugates have been reported.
Dervan has described the use of a lexitropsin-EDTA-Fe complex
for ‘‘affinity cleaving’’ near AT-rich sites.[50–52] Ferrocene has
been used to connect two polyamide strands.[53] Iron-bleomycin
analogs have been attached to lexitropsins at the N-[54–55] and C-
[56–57] termini, showing that the polyamide can overturn the
inherent GC-selectivity of the bleomycin portion. Bleomycin
analogs have also been attached to lexitropsins in conjunction with
cobalt.[58] Copper- salen,[59] -phenanthroline,[60–61] –pep-
tide[62] and –bipyridine[63–64] complexes have been conjugated
to lexitropsins, as well as a copper complex consisting of an N-
terminal peptide and C-terminal intercalator.[65] Other metal
complexes associated with lexitropsins include manganese,[66]
vanadium,[67] tungsten,[68] platinum[69–71] and the radionu-
clide technetium-99m.[72] The first example of a zinc complex
attached to a lexitropsin was only recently reported.[73] To date
there have been no reports of lexitropsins bound to azamacro-
cycles or azamacrocyclic complexes, which is surprising given how
widely such frameworks are used in coordination chemistry.[74]
The thermodynamics of DNA binding with lexitropsin-metal
complex conjugates have not been examined, nor has the effect of
varying the metal coordinated within the same lexitropsin analog
been investigated. It is also frequently the case that metal-
lexitropsin conjugates are not characterized prior to their
interaction with DNA, and are assumed to form in situ. This
report addresses these areas.
We recently became interested in the attachment of azamacro-
cycles to motifs that recognize biological molecules. We have
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azamacrocycle’s interaction with DNA by changing the nature
of an amino acid appended to the macrocycle,[75] and created a
metal complex whose primary coordination environment changes
in response to the binding of a protein.[76] For a more general
approach to the study of azamacrocycle-DNA interactions, a
generic method for ensuring proximity of the azamacrocycle
complex to DNA is required. If azamacrocycles can be reliably
targeted in this way, it becomes possible to study their labeling and
nuclease functions for diverse applications. This report describes
the first synthesis of lexitropsin-cyclam complexes and the nature
of their interaction with oligonucleotides. Cyclam was chosen as
the azamacrocycle in this study since this ligand has found wide
use in biology and medicine owing to its robust and well
characterized coordination chemistry.[77]
Results
Synthesis
The targets of the synthesis were lexitropsin-cyclam conjugates
4a–c (Figure 1), formed by the union of the polyamide binding
motif and the azamacrocycle through the synthetically facile
copper-catalyzed azide-alkyne Huisgen cycloaddition (a so-called
‘click’ reaction).[78] Compounds 1a–c[79–80] and propargylated
cyclam[81] were prepared according to literature methods
(Scheme S1 and Text S1). Four aspects of these structures are of
interest in comparison to literature lexitropsins: a) lack of the N-
terminal formamido group, b) attachment of an unprecedented
group (cyclam) to the C terminus, c) inclusion of an alkyl spacer
between the azamacrocycle and the recognition motif and d)
complexation of metal ions (copper and zinc). It was anticipated
that these features would combine to provide structures capable of
binding DNA, and the influence of each feature is discussed in
more detail below.
1) Ligand Synthesis. The pyrrole acids 1a–c were coupled
with commercially-available 3-aminopropyl azide to give 2a–c
which were coupled to the protected propargyl cyclam in good
yields. Removal of the Boc groups to give the free amines
proceeded smoothly. It was noted that intermediates in the
synthesis of 1 containing deprotected amines (i.e. after removal of
Boc groups from the aminopyrrole moiety) decomposed after a few
hours at room temperature, and were therefore typically used
immediately after isolation. Compounds 2 and 3 were found to be
hygroscopic, but were effectively handled (and weighed) as
ethereal solutions.
2) Metal Complexation. Given the novelty of these cyclam
ligands it was important to characterize their metal complexation
prior to assessing their interactions with DNA. Model compound
4a, containing a single pyrrole in the side chain, was employed for
these studies as representative of the other compounds. Titration
with copper(II) chloride in methanol led to the appearance of a
peak in the UV-visible spectrum (lmax=590 nm, e=
414 M
21cm
21) that reached a maximum absorbance with the
addition of one equivalent of CuCl2, indicating the formation of a
well-defined complex (Figure 2). The lmax is similar to previously-
reported scorpion cyclam complexes of copper.[76] The sharpness
of the transition at one equivalent of added metal salt is notable
(Figure 2, inset), and implies a high association constant between
the metal ion and ligand as has been seen with related complexes
(although this was not quantified as part of the current study).
[81–82] A complexation stoichiometry of 1:1 was confirmed
by a Job plot measured at the lmax of 590 nm (Figure S22;
for a titration curve between CuCl2 and compound 4c, see Figure
S23).
1H NMR titration was used to examine the complexation
between the model ligand 4a and zinc(II) chloride in CD3OD by
the addition of the metal salt in 0.2-equivalent increments to a
solution of 4a up to a maximum of 1.2 equivalents (Figure 3).
While much of the
1H NMR spectrum is complex, disappearance
of the signal due to the triazole proton at 7.91 ppm can be
conveniently monitored during the addition. The titration clearly
shows a 1:1 complexation stoichiometry. The appearance of
several new peaks in the 7.9–8.3 ppm region of the spectrum
indicates the presence of interconverting species in solution that
are presumably cyclam conformational isomers/diastereomers.
This is supported by an approximately 1:1 correspondence
between the integral for the peaks shown at 0 equivalents of
added ZnCl2 and the new peaks shown in the spectrum after
addition of 1.50 equivalents of metal salt.
Isothermal Titration Calorimetry
The DNA binding characteristics of cyclam-lexitropsin conju-
gates 4, 5 and 6 were examined using two palindromic
oligonucleotides d-(GGGATATATCCC)2 (oligo I) and d-
(GGGCGGCCGCCC)2 (oligo II). The GC rich ends were chosen
to stabilise the DNA duplex and encourage annealing; these
sequences have melting temperatures of 36uC and 48uC
respectively, meaning that they are duplexes under the conditions
of the ITC experiments (25uC). The middle section of the
oligonucleotide sequences was designed to probe for AT vs.G C
selectivity, and the question arose as to whether the exact sequence
of the bases in the variable region is important. Netropsin binds
less well to alternating AT sequences than continuous runs (2 or
more) of the two bases.[83] Bisbenzimidazole minor groove
binders are very sensitive to the precise arrangement, and even
sequence direction, of the bases within an AT-rich sequence[84]
Figure 1. Scheme for reagents and conditions employed in
ligand synthesis. i) EDC?HCl, HOBt, N,N-diisopropylethylamine, 3-
azidopropylamine, dichloromethane, rt; ii) CuI (10 mol%), sodium
ascorbate (20 mol%),
tBuOH/water (1:1), propargyl tri-boc protected
cyclam, rt; (iii) TFA/dichloromethane (1:5), 6 h, rt, (iv) CuCl2 or ZnCl2
solution in methanol, 5 min, rt.
doi:10.1371/journal.pone.0017446.g001
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sensitivity.[85] Given the difficulty of predicting the behaviour of a
novel lexitropsin, no attempt was made to pre-judge the behaviour
of the present complexes and design specific cognate sequences.
However a d(polyA).d(polyT) sequence was avoided since such
oligonucleotides have unusual structures and hydration character-
istics that might obfuscate a fair comparison with the GC-rich
sequence.[86–88] The middle sequence of six bases is long enough
to give meaningful binding data based on what is known of the
distamycin/netropsin binding site.[15–16,42,89] and the n+1 rule
of thumb of lexitropsin binding.[90] Short, model oligomers of this
type are accurate models for binding characteristics with longer
DNA sequences.[91]
DNA binding studies with small molecules are very sensitive to
the salt concentration of the solution.[65,79–80,92] HEPES buffer
was chosen for all experiments based on literature prece-
dents.[63,93] Ethylenediaminetetraacetic acid (EDTA) is some-
times also employed in DNA binding experiments of this type, but
was not added in the present study since its metal-coordinating
ability has the potential to make the role of the metal in the ligand
complex ambiguous.
The concentrations of oligonucleotide and complex were
10 mM and 1000 mM respectively. Each injection (2 mL) by the
calorimeter contained 1 equivalent of ligand with respect to the
oligonucleotide. Control titrations were performed with ethidium
bromide to validate this experimental method. EtBr was chosen
for convenience; despite being an intercalator, it was important to
verify correspondence between experimental and literature ITC
values. The values obtained for coordination of ethidium bromide
with the AT-rich oligonucleotide (DG=227.6 kJ mol
21,
DH=244.8 kJ mol
21, DS=256.9 J mol
21 K
21) are in broad
agreement with those in the literature for the titration between
ethidium bromide and the related poly[d(A-T)]-poly[d(A-T)]
(DG=238.1 kJ mol
21, DH=241.8 kJ mol
21, DS=212.6 J
mol
21 K
21),[87] and as expected given its intercalative binding
mode, similar binding constants were obtained for the AT-rich
and GC-rich oligonucleotides (ca. 0.7610
5 M
21).
The data obtained gave Ka, DH and DS values for each
titration, as well as stoichiometry of binding; values of DG are
calculated (Table 1). No detectable binding was observed between
either oligonucleotide and the mono- or di-pyrrole compounds 4a
and 4b, cyclam itself and its copper and zinc complexes, as well as
Figure 2. UV-vis spectrum for the titration of a solution of CuCl2 with compound 4a in methanol (graphical representation of raw
data). The increase in absorbance reaches a maximum after the addition of 1 eq CuCl2 (inset).
doi:10.1371/journal.pone.0017446.g002
Figure 3. Zinc(II) chloride titration with model compound 4a monitored by
1H NMR spectroscopy. The ratio of the integrals of the
starting material (d 7.91 ppm) vs. the other peaks reaches a maximum after the addition of 1 eq ZnCl2 (inset).
doi:10.1371/journal.pone.0017446.g003
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with a benzyl sidechain in place of the oligopyrrole moiety.[76]
(See Figure S24)
Strong binding was observed between the three-pyrrole
conjugate 4c and both of its metal complexes 5c and 6c with
the AT-rich oligonucleotide I (Figure 4), but no binding was
observed between any of these compounds and the GC-rich
oligonucleotide II. The strength of the interactions between the
AT-rich oligonucleotide and the unmetallated ligand 4c, its
copper complex 5c and zinc complex 6c were approximately of
the same magnitude (Table 1).
Discussion
General remarks
The binding of the three-pyrrole compound and its complexes
to AT-rich DNA occurred with a binding constant of ca. 1–
3610
5 M
21. This strength of association compares favourably
with other metal complex derivatives of lexitropsins noted in the
introduction and related three-pyrrole lexitropsins,[89] but is less
than that of natural lexitropsins such as distamycin itself, which
has a reported Ka of ca.3 610
8 M
21 for related sequences.[87]
Selectivity of binding
While compound 4c and its metal complexes bind the AT-rich
oligonucleotide I reasonably strongly, there is no detectable
binding with the GC-rich oligonucleotide II, indicating that these
lexitropsins distinguish AT-rich regions of DNA very effectively. It
is usual for lexitropsins to exhibit a selectivity for certain regions of
bases, but typically some binding is observed between the
lexitropsin and non-cognate sequences; for example netropsin
binds to poly[d(GC)].poly[d(GC)] with 38% of the enthalpy
change with which it binds poly[d(AT)].poly[d(AT)].[91] The
complete absence of observable binding with the GC-rich
sequence, as is the case here, is unusual. This level of selectivity
presumably arises from multiple disfavoured interactions in the
binding with the GC-rich oligonucleotide; the enthalpic penalty
for base:lexitropsin mismatch is not linearly additive, with single
mismatches being quite well tolerated far better than multiple
mismatches.[94]
Number of pyrroles required for binding
The results above clearly show that three pyrroles are required
for synthetic lexitropsins of this type to bind to AT-rich DNA, a
figure that is consistent with the literature for related com-
Table 1. Binding data for selected ligands and complexes with d-(GGGATATATCCC)2 (I) and d-(GGGCGGCCGCCC)2 (II). nd=no
detectable binding.
Sample Oligo No. sites Ka (610
5 M
21) DH (kJ mol
21) DS (J mol
21 K
21) DG (kJ mol
21)
4c II nd - - - -
I2 . 3 60.1 2.760.3 219.960.6 37.462.2 23161.8
5c II nd - - - -
I2 . 3 60.2 1.260.2 220.261.7 29.565.9 22964.9
6c II nd - - - -
I2 . 5 60.2 1.560.3 220.862.0 29.566.9 23065.7
All entries are averages of two titration experiments. For a description of the calculation of errors, see Text S1.doc and Spreadsheet S1.xls.
doi:10.1371/journal.pone.0017446.t001
Figure 4. Representative binding affinity data for ligand 4c (left), 5c (centre) and 6c (right) to ANT-rich oligonucleotide I.
doi:10.1371/journal.pone.0017446.g004
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pyrroles, the two charged groups at either end of the structure (and
analogs[58,68]) can compensate by giving rise to favourable
electrostatic interactions with the helix.[16]
Cyclam as a new C terminal modification
The greatest variation in the structure of these new lexitropsins
compared to known analogs is the addition of cyclam (an
alkylamine ring) to the C-terminus. A C-terminal methylene
spacer between the pyrrole rings and the cyclam was employed in
the design, since methylene groups form favourable van der Waals
interactions with terminal A/T base pairs,[95] and the attachment
of alkylamines to lexitropsins without such a spacer leads to poor
DNA binding characteristics.[96]
Cyclam is an important modification because the nature of the
C-terminal alkylamine can significantly alter lexitropsin binding
strength. Apparently trivial changes to the alkylamine tail of
lexitropsins can change their binding affinity for their cognate
sequence by up to two orders of magnitude (Table S1, Entries 1–
2).[96] Significant changes in the identity of the heterocyclic bases
in lexitropsins with alkylamine tails can affect their binding
abilities to a lesser degree (Table S1, Entries 3–4).[42] Thus while
selectivity for nucleic acid sequences can obviously be imparted by
certain sequences of Py and Im components, the nature of the
alkylamine tail also makes an essential contribution to the overall
binding strength.
The lexitropsin conjugates described herein clearly show that
cyclam is well tolerated as a C-terminal modification to natural
minor groove binders. Both the unmetallated ligand and metal
complexes containing zinc and copper are tolerated to approxi-
mately the same degree, though the former has a slightly higher
binding affinity. While this may at first seem surprising on purely
electrostatic grounds (discussed further below), it should be
remembered that the unmetallated cyclam ring, drawn as neutral
in Figure 1 will be doubly protonated at neutral pH.[97]
Interestingly C-terminal alkylamine tails on other minor groove
binders can act as a GC-directing motif, for example the
piperazine ring in the compound Hoechst 33258, which exerts
this change essentially on the steric grounds of requiring a wider
minor groove.[98] The azamacrocycle cyclam does not have this
effect in analogs 4c–6c.
N-Terminal changes
Removal of the N-formamido moiety from lexitropsins can
significantly reduce their binding affinity for DNA,[89,99] but
does not necessarily eliminate it.[100] Many analogs are known in
which this group has been replaced with related structures that
modify binding affinities,[44,99,101–102] and significant changes
in this region have been tolerated, for example some of the metal
complex-lexitropsin conjugates described in the introduc-
tion.[55,60,65,72] However, the reduction in binding affinity for
Py-Py-Py (the lexitropsin scaffold of interest here) when the N-
formamido moiety is removed is smaller than for other lexitropsins
(one order of magnitude, from ca.1 0
5 to ca.1 0
4 M
21 for
formamide-PyPyPy vs. PyPyPy, Table S1, Entries 5–6).[89] It is
thought that the formamide affects the way the molecule stacks as
a dimer in the minor groove,[89] but poly-Py lexitropsins can bind
as monomers.[42] The effect of removing the N-formyl group also
varies with lexitropsin structure, and the effects are different for
hairpin- and cross-linked lexitropsins.[103] As might be expected
from these observations, the binding affinities observed for the
novel lexitropsin conjugates in the present work imply that the
removal of the terminal N-formamido is not prohibitive for
binding.
Metal preference and metallated vs. unmetalated ligands
The cyclam-lexitropsin conjugates described here show essen-
tially the same binding characteristics whether the cyclam is
unmetalated vs. when copper or zinc is coordinated. The
implication is that the metal complex plays no role in binding.
The similar size of these conjugates to literature examples in which
the metal is known to interact with the DNA, suggest that the
cyclam should be geometrically able to do so. One possible
explanation for the apparent absence of metal-DNA interactions
in our systems is that the scorpion ligand structure, in which the
triazole is coordinated to the metal ion, effectively hides the metal
and prevents it from binding the oligonucleotide. In contrast to
previous results with an avidin/biotin couple,[76] it appears that
binding of the DNA does not lead to altered metal coordination in
the scorpion complex. In a report of a cobalt-bleomycin-
lexitropsin compound the metal-free ligand had a binding affinity
with its target (4.75610
4 M
21) that was only slightly lower than
that for the metalated version (2.26610
5 M
21) and a similar
‘‘shielding’’ of the metal from the DNA backbone by bulky ligand
substituents was proposed.[58] In contrast Li et al. recently
reported a Zn-lexitropsin conjugate based on the bis(2-benzimi-
dazolyl-methyl)amine scaffold, in which the metal is available for
coordination, and which exhibited a 3-fold enhancement of
affinity for AT-rich oligonucleotides compared to the metal-free
ligand.[73]
To verify whether the cyclam in the ligand is well placed to form
favourable interactions with the phosphate backbone, molecular
modeling was carried out on the complex formed between the AT-
rich oligonucleotide and compound 4c (as representative of all the
ligands tested). The interaction was modeled by taking the
geometry-optimized DNA oligonucleotide and after inserting an
optimized dimer of cyclam ligands into the minor groove, the
resulting DNA-dimer complex was then subjected to geometry
optimization. The results of this procedure can be seen in Figure 5.
Whether a lexitropsin tail is in the correct position to interact with
Figure 5. Model of the interaction between the AT-rich
oligonucleotide and ligand 4c.
doi:10.1371/journal.pone.0017446.g005
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mode of binding.[104] It is clear here, however, that the expected
binding mode is observed for the lexitropsin in the minor groove
(offset stacked dimer), yet the cyclam is situated well outside the
double helix and appears to form no favourable interactions with
the DNA backbone. An identical mode of binding was seen when
one of the metal complexes (6c) was modeled in this way.
Enthalpic vs. entropic components of binding
A consideration of both binding enthalpy and entropy is
important, rather than solely the binding free energy, since
enthalpic and entropic changes in small molecule-DNA binding
can compensate for one another to give a misleading free energy
change.[87] ITC can give valuable information above and beyond
what may be gleaned from other analytical methods.[105–106]
Certain mechanisms of DNA binding can give rise to specific
signatures in the resulting thermodynamic data – thus minor
groove binding interactions tend to entropically driven, while
intercalation is often enthalpically-driven; lexitropsins are an
exception to this rule of thumb and the –TDS term for lexitropsin-
DNA binding can be large.[107]
The lexitropsins 4c–6c do not show the enthalpy-entropy
compensation that is expected[87,108] but not absolutely
required[109] in drug-receptor interactions. The binding is
enthalpy-dominated, but not overwhelmingly so, with entropy
accounting for 30–40% of the change in free energy upon binding.
The entropic gain is largest for the unmetallated ligand. The
favourable gain in entropy upon binding the lexitropsins may arise
from the loss of some DNA-bound water from the ‘spine of
hydration’.[110–111] though there is still disagreement as to
whether there is net water loss or gain upon minor groove binding
more generally.[107] The fact that, in contrast to distamycin
itself,[87] this gain in entropy is not offset by the sizeable
conformational constraint imposed on the lexitropsin by the
binding event,[16,112] may be due to the lower binding affinity of
these synthetic vs. the natural ligands.
Binding stoichiometry
The compounds in the present work bind with a 2:1
stoichiometry to AT-rich oligonucleotides, despite being pyrrole
rich and being potentially multiply charged under the conditions
employed. It is known that lexitropsins can bind to DNA and
oligonucleotides with either a 1:1[16,113] or 2:1[114–116]
stoichiometry depending on factors including the nucleobase
sequence and the identity and concentration of the ligand.[117]
The level of cooperativity in binding also depends on the base
sequence and the nature of the polyamide.[42,118] Pyrrole-based
polyamides (in contrast to those containing other heterocycles such
as imidazoles) often bind with negative cooperativity, which can
arise from a positive enthalpic cooperativity but strongly
unfavourable entropic factors for the binding of the second
ligand.[119–120] However, there are cases where little coopera-
tivity is shown.[121] It is sometimes expected that pyrrole-based
lexitropsins will bind with 1:1 stoichiometry because DNA
sequences consisting exclusively of A and T bases have a narrower
minor groove, but this is not always the case.[115] Charge is an
important factor in determining binding stoichiometry; it is
expected that monocationic lexitropsins will bind oligonucleotides
with a 2:1 stoichiometry, unlike dicationic netropsin that typically
binds with 1:1 stoichiometry.[119]
Given the 2:1 binding stoichiometry of lexotropsins 4c–6c to
oligo I, it might be expected that the association constants for the
first and second binding events could be deconvoluted, or that the
two binding events would be clear from a discontinuity in the ITC
data. However since there is no such discontinuity, binding is
either statistical (no cooperativity) or there is cooperativity but two
molecules of the lexitropsin bind simultaneously to a single
oligonucleotide, rather than in a statistical 1:1 binding.[118,120]
Such cooperativity has been shown for the binding of distamycin
to d(CGCATATATGCG)2.[122] Hence the value for Ka should
formally be thought of as a combination of the two contributing
binding events, i.e. (K1K2)
1/2.
Conclusion
The magnitude and selectivity of the binding exhibited by these
cyclam-polyamide compounds is gratifying for the reasons detailed
above. Despite lacking a terminal formamide, not necessarily
incorporating an optimized DNA sequence for binding, and in the
face of literature precedent showing that unoptimised alkylamines
can significantly reduce the binding efficiency of lexitropsins, the
Ka values observed for the three conjugates that exhibit binding
are high, with complete selectivity for the AT-rich oligonucleotide
over the GC-rich sequence. The data (and modeling) show that in
the cases studied, there was little influence of the nature of the
cyclam and coordinated metal on the degree of DNA binding.
This arises because once the lexitropsin binds as a dimer in the
minor groove, the cyclam is positioned beyond the backbone of
the DNA helix.
There is considerable scope for modifying these structures to
optimize binding, and to position the cyclam and its complexes for
interaction with the DNA backbone. Of particular interest will be
to vary the structure of the scorpion ligand to facilitate metal
interaction with the DNA helix upon binding, so as to permit the
future development of sequence-specific DNA cleavage. Future
study of the potential nuclease activity of the metal centre would
likely employ the related azamacrocycle cyclen, the metal
complexes of which are known to promote phosphodiester
cleavage in model systems[123] and AT-specific oligonucleotide
binding (when conjugated to intercalating moieties).[124] The
synthetic accessibility of these conjugates makes such optimization
and diversification straightforward.
Another future application of complexes of this type is as
imaging agents for the presence of specific DNA sequences using
complexes whose optical properties change upon binding. The
attachment of cyclams also offers potential improvements in the
cell permeability of the resulting lexitropsins: it is known that zinc
sensors based on related triazole-cyclam motifs are cell-perme-
able,[81] while hairpin polyamides themselves have limited
cellular penetration.[9]
Materials and Methods
A) General Procedures
Synthesis. Novel compounds are described below; all other
compounds are described in the Scheme S1 and Text S1. The
procedure used for the couplings of the 1-methylpyrroles intolonger
chains was adapted from literature[79–80] but using EDC?HCl
and HOBt as the coupling reagents. The oligonucleotides d-
(GGGATATATCCC)2 and d-(GGGCGGCCGCCC)2 and were
purchased from Geneworks (Adelaide, Australia; HPLC purified).
Reagents were obtained from Sigma Aldrich, Fluka, Novabiochem
or Alfa Aesar and used directly without further purification. Milli-Q
water was used in all physical measurements. NMR spectra for
novel compounds are provided along with the .dx files (NMR Data
S1.zip) which may be read by any NMR processing software.
UV-vis. UV-vis spectra were recorded on a Cary 4E UV-vis
spectrophotometer between 290 and 900 nm using a 1 cm61c m
quartz cuvette. For the copper(II) complex titration experiment,
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methanol (1 mL). Copper(II) chloride (73.4 mM) was added in 0.2
eq aliquots until 2 eq had been added. Measurements were taken
after 30 s of stirring. For the Job plot a series of metal and ligand
mixtures was prepared, such that the total molarity was the same
while changing the metal and ligand ratio at 0.2 eq intervals.[125]
The maximum absorbance obtained from these solutions at a
particular wavelength was plotted against the mole ratio of ligand.
NMR.
1H and
13C Nuclear Magnetic Resonance spect-
roscopy was performed on either a Bruker Avance DPX 200
Spectrometer or a Bruker Avance DPX 300 Spectrometer. For the
zinc titration experiment, the cyclam ligands were dissolved in
CD3OD (to 5.6 mM) and a solution of zinc(II) chloride in CD3OD
(73.4 mM) was titrated to 1.2 eq in 0.2 eq increments.
Calorimetry. DNA binding studies were performed on an
iTC200 Microcalorimeter made of HastelloyH Alloy C-276. The
system was operated at 25uC with a coin cell design with a
capacity of 200 mL and a titration syringe with a capacity of
40 mL. The amount injected was 2 mL per 150 seconds with a
stirring rate of 1000 rpm. The stock solution of DNA in the
calorimeter chamber was 10 mM in 10 mM HEPES buffer
containing 100 mM NaCl and the ligand. The stock ligand
solution (1000 mM) was diluted to a concentration of 10 mM with
the buffer solution prior to ITC experiments and was titrated into
the DNA solution. Single stranded DNA oligos were supplied by
Geneworks and dissolved in buffer (10 mM HEPES, 100 mM
sodium chloride, pH 7.0) and shaken gently at 25uC for 2 days to
yield double stranded oligonucleotides to a stock concentration of
100 mM determined using a Nanodrop 1000 spectrophotometer
(Thermo scientific version 3.6.0). A correction was made for the
heat of dilution of the ligands, estimated from the peaks obtained
from injections at the end of a given ITC experiment (following
saturation).
Metal complex synthesis for ITC experiments: to the ligand (1
eq) was added a solution of copper(II) chloride solution (73.4 mM,
1.0 eq) in methanol or zinc(II) chloride solution (73.4 mM, 1.0 eq)
in methanol. The methanol was removed under reduced pressure
and HEPES buffer (10 mM with 100 mM NaCl) was added to
obtain a final stock ligand concentration of 1000 mM which was
kept at 0uC. These complexes were used directly in DNA binding
studies.
B) Typical General Synthetic Procedures
Peptide coupling (A). To the carboxylic acid (1.0 eq) and
amine (1.3 eq) in anhydrous dichloromethane (solution is ca.
125 mM in acid) were added EDC?HCl (1.2 eq), HOBt (1.2 eq)
and N,N-diisopropylethylamine (3.0 eq). The reaction mixture was
stirred at rt under nitrogen for 12 h. Sodium bicarbonate solution
(10% w/v) was added dropwise to the reaction mixture until
pH 10 was reached and the reaction mixture was extracted with
dichloromethane (3 times). The combined organic phases were
dried (Na2SO4) and concentrated under reduced pressure.
‘Click’ reaction (B). Alkyne (0.93 eq) and azide (1.0 eq) were
dissolved in a mixture of water/tert-butanol (1:1, to give 100 mM
solution in azide) and stirred at 27uC under nitrogen. A solution of
copper(II) sulfate pentahydrate (0.31 mmol, 0.1 eq) and sodium
ascorbate (0.62 mmol, 0.2 eq) in water (to give a solution that was
125 mM in copper) was added to the reaction mixture and stirring
was continued for 16 h. The reaction was quenched with saturated
sodium bicarbonate solution until pH 10 was reached and the
mixture extracted with dichloromethane (3 times). The combined
organic phases were dried (Na2SO4) and concentrated under
reduced pressure.
TFA deprotection of Boc groups (C). To the Boc-protected
compound (1.0 eq) in anhydrous dichloromethane (300 mM) was
added trifluoroacetic acid (10 eq) dropwise and stirring was
continued at rt for 6 h. The reaction was cooled to 0uC before the
addition of water (same volume as dichloromethane). Sodium
hydroxide (1 M) was added dropwise until pH 10 was reached.
The mixture was extracted with chloroform (3 times). The
combined organic phases were dried (Na2SO4) and concentrated
under reduced pressure.
Base deprotection of ester group (D). To the ester-
protected compound (1.0 eq) in a mixture of water/methanol
(1:1, 5 mM) was added sodium hydroxide (0.25 M, 4.0 eq) and the
solution was heated at reflux for 3 h under nitrogen. The reaction
mixture was washed with ethyl acetate (2 times) and the aqueous
phase was acidified to pH 3 with hydrochloric acid (1 M) and was
extracted with ethyl acetate (3 times). The combined organic
phases were dried (Na2SO4) and concentrated under reduced
pressure.
Complexation of copper(II) and zinc(II) cyclam
derivatives (E). To N-functionalized cyclam (1.0 eq) was
added copper(II) chloride or zinc(II) chloride solution in
methanol (73.4 mM, 1.0 eq) and stirring was continued at rt for
10 min. Methanol was evaporated in vacuo and HEPES buffer
(10 mM containing 100 mM NaCl) was added to give a final
ligand concentration of 1000 mM.
C) Molecular Modeling
DNA oligonucleotide d-(GGGATATATCCC)2 was construct-
ed as the B-form regular helix using the Maestro 9.1 (Maestro,
v9.1.107, Schro ¨dinger, LLC) graphical user interface. Cyclam
ligand structures were built, manipulated and adjusted for
chemical correctness using Maestro, employing MacroModel 9.8
(Macro-Model, v9.8, Schro ¨dinger, LLC). Geometry minimizations
were performed on all cyclam ligands using the OPLS_2005
(MacroModel) force field and the Truncated Newton Conjugate
Gradient (TNCG). Optimizations were converged to a gradient
RMSD below 0.05 kJ/mol or continued to a maximum of 1000
iterations, at which point there were negligible changes in RMSD
gradients.
D) Synthesis of Novel Compounds
N-(3-Azidopropyl)-1-methylpyrrole-2-carboxamide 2a.
1-Methylpyrrole-2-carboxylic acid 1a ( 0 . 2 4g ,2 . 0m m o l ,1e q )
and 3-azidopropylamine (0.26 g, 2.6 mmol, 1.3 eq) were
coupled using general procedure A with purification by flash
column chromatography (1:1 ethyl acetate/hexane, RF 0.31)
yielding 2a (0.34 g, 82%) as a light yellow oil; IR (ATR) 2091,
1631 cm
21;
1HN M R(200 MHz, CDCl3) d 6.69–7.72 (1H, m,
Ar), 6.51 (1H, dd, J 3.9 & 1.6, Ar), 6.07 (1H, dd, J 3.9 & 2.6,
A r ) ,5 . 9 6 – 6 . 0 5( 1 H ,b rs ,N H ) ,3 . 9 4( 3 H ,s ,C H 3), 3.46 (2H, t, J
6.6 Hz, H
1), 3.41 (2H, t, J 6.6 Hz, H
3), 1.86 (2H, qn, J 6.6 Hz,
H
2) (Figure S1);
13CN M R(50.3 MHz, CDCl3) d 161.9 (C=O),
127.4 (Ar), 125.2 (Ar), 111.5 (Ar), 106.7 (Ar), 48.8, 36.2, 36.0,
28.6 (Figure S2); MS (APCI) m/z 108.0 (C6H8NO
+,8 6 % ) ,
208.0 (MH
+,2 9 % ) ;HRMS (APCI) calcd for C9H14N5O
+
208.11984 found 208.11929 (MH
+).
N-(3-Azidopropyl)-1-methyl-4-(1-methyl-1H-pyrrole-2-ca-
rboxamido)-1H-pyrrole-2-carboxamide 2b. Methylpyrrole
amide carboxylic acid 1b (104 mg, 0.42 mmol, 1 eq) and 3-
azidopropylamine (55 mg, 0.55 mmol, 1.3 eq) were coupled
according to procedure A, with purification by flash column
chromatography (ethyl acetate, RF 0.59) yielding 2b (122 mg,
88%) as a light yellow oil; IR (CHCl3) 3326, 2096, 1640,
1535 cm
21;
1H NMR (300 MHz, CDCl3) d 7.74 (1H, br s, NH),
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Ar), 6.55–6.57 (1H, m, Ar), 6.05–6.15 (2H, m, Ar), 3.95 (3H, s,
NCH3), 3.86 (3H, s, NCH3), 3.35–3.55 (4H, m, CH2CH2CH2N3),
2.74–3.25 (1H, br s, NH), 1.77–1.88 (2H, m, CH2CH2CH2N3)
(Figure S3);
13C NMR (75.5 MHz, CDCl3) d 161.8 (C=O), 159.4
(C=O), 128.5 (Ar), 125.4 (Ar), 123.2 (Ar), 121.3 (Ar), 118.9 (Ar),
112.0 (Ar), 107.4 (Ar), 103.5 (Ar), 49.4, 36.9, 36.8, 36.5, 28.9
(Figure S4); HRMS (APCI) calcd for C15H19N7NaO2
+ 352.14979
found 352.14924 (MNa
+).
N-(3-Azidopropyl)-1-methyl-4-(1-methyl-4-(1-methyl-1H-py-
rrole-2-carboxamido)-1H-pyrrole-2-carboxamido)-1H-pyrro-
le-2-carboxamide 2c. Pyrrole amide carboxylic acid 1c (104 mg,
0.42 mmol, 1 eq) and 3-azidopropylamine (55 mg, 0.55 mmol, 1.3
eq) were coupled using procedure A. The residue was purified by
flash column chromatography (ethyl acetate, RF 0.59) yielding 2c
(122 mg, 96%) as a light yellow oil;
1HN M R(300 MHz, CDCl3) d
8.46 (1H, br s, NH), 8.15 (1H, br s NH), 8.05 (1H, br s, NH), 6.88–
6.94 (3H, m, Ar), 6.80–6.82 (1H, m, Ar), 6.68–6.71 (1H, m, Ar),
6.61–6.67 (1H, m, Ar), 6.21–6.25 (1H, m, Ar), 4.09 (3H, s, NCH3),
3.98 (3H, s, NCH3), 3.95 (3H, s, NCH3), 3.42–3.70 (4H, m,
CH2CH2CH2N3), 1.93–2.10 (2H, m, CH2CH2CH2N3) (Figure S5);
13CN M R(75.5 MHz, CDCl3) d 161.9 (C=O), 159.6 (C=O),
159.0 (C=O), 128.4 (Ar), 125.3 (Ar), 123.2 (Ar), 122.9 (Ar), 121.5
(Ar), 121.3 (Ar), 119.5 (Ar), 119.0 (Ar), 112.3 (Ar), 107.3 (Ar), 104.0
(Ar), 103.5 (Ar), 49.2, 36.8, 36.7, 36.4, 36.4, 28.8 (Figure S6); MS
(ESI) m/z 452.1 (MH
+, 68%), 474.3 (MNa
+,7 5 % ) ;HRMS (ESI)
calcd for C21H25N9NaO3
+ 474.19781 found 474.19726 (MNa
+).
For cyclam-based compounds an NMR assignment convention
is used as shown in Figure 6.
Tri-tert-butyl 11-((1-(3-(1-methyl-1H-pyrrole-2-carboxa-
mido)propyl)-1H-1,2,3-triazol-4-yl)methyl)-1,4,8,11-tetraaz-
acyclotetradecane-1,4,8-tricarboxylate 3a[76]. Tri-Boc pro-
pargyl cyclam (0.70 g, 1.30 mmol, 0.93 eq) and azide 2a (0.29 g,
1.4 mmol, 1 eq) were reacted together according to procedure B,
giving a white gum which was purified by flash column
chromatography (ethyl acetate, RF 0.20) yielding 3a (0.79 g, 81%)
as a white solid; mp 72–74uC; IR (ATR) 3366, 1687, 1544 cm
21;
1HN M R(300 MHz, CDCl3) d 7.51 (1H, br s, H
g), 6.69–6.72 (1H,
m, Ar), 6.59–6.66 (1H, m, Ar), 6.30–6.57 (1H, br s, NH), 6.05–6.09
(1H, m, Ar), 4.44 (2H, t, J 6.7 Hz, H
h), 3.93 (3H, s, NCH3), 3.74
(2H, s, H
f), 3.68–3.85 (2H, m, H
j), 3.20–3.50 (12H, m, H
a), 2.58–
2.70 (2H, m, H
b), 2.40–2.50 (2H, m, H
c), 2.16–2.36 (2H, m, H
i),
1.80–2.00 (2H, m, H
d), 1.65–1.80 (2H, m, H
e), 1.44 (27H, s,
C(CH3)3) (Figure S7);
13C NMR (50.3 MHz, CDCl3) d 162.0,
155.4, 155.1, 127.5, 125.1, 122.6, 111.8, 79.1, 77.6, 77.0, 76.4,
59.9, 46.0–47.5 (multiple peaks), 36.3, 35.9, 30.1, 28.1 (Figure S8);
MS (ESI) m/z 746.3 (MH
+, 61%), 768.3 (MNa
+, 100%), HRMS
(ESI) calcd for C37H64N9O7
+ 746.49287 found 746.49162 (MH
+).
Tri-tert-butyl 11-((1-(3-(1-methyl-4-(1-methyl-1H-pyrrole-
2-carboxamido)-1H-pyrrole-2-carboxamido)propyl)-1H-1,2,
3-triazol-4-yl)methyl)-1,4,8,11-tetraazacyclotetradecane-1,4,
8-tricarboxylate 3b[76]. Tri-Boc propargyl cyclam (209 mg,
0.39 mmol, 0.93 eq) and azide 2b (138 mg, 0.42 mmol, 1 eq) were
reacted together according to general procedure B yielding a light
yellow oil, which was purified by flash column chromatography
(ethyl acetate, RF 0.18) yielding 3b (284 mg, 78%) as a hygroscopic
white gum; IR (ATR) 3337, 2974, 1681 cm
21;
1H NMR
(300 MHz, CDCl3) d 8.05 (1H, s, NH), 7.50 (1H, s, H
g), 6.55–
6.80 (5H, m, Ar, NH), 6.08 (1H, dd, J 3.9, 2.6 Hz, Ar), 4.38–4.50
(2H, m, H
h), 3.95 (3H, s, N(CH3)), 3.88 (3H, s, N(CH3)), 3.68–3.78
(2H, m, H
j), 3.20–3.45 (14H, m, H
a,f), 2.57–2.65 (2H, m, H
b), 2.36–
2.52 (2H, m, H
c), 2.12–2.23 (2H, m, H
i), 1.80–1.96 (2H, m, H
d),
1.63–1.79 (2H, m, H
e), 1.43 (27H, s, 3 C(CH3)3) (Figure S9);
13C
NMR (50.3 MHz, CDCl3) d 162.1, 159.3, 155.8, 155.6, 128.3,
125.5, 122.9, 121.6, 119.1, 111.9, 107.3, 103.6, 79.6, 46.0–47.8
(several peaks), 36.8, 36.5, 36.3, 29.9, 28.5 (Figure S10); MS (ESI)
m/z 868.4 (MH
+, 56%), 890.6 (MNa
+, 100%); HRMS (ESI) calcd
for C43H70N11O8
+ 868.54088 found 868.54034 (MH
+).
Tri-tert-butyl 11-((1-(3-(1-methyl-4-(1-methyl-4-(1-methyl-
1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carboxamido)-1H-
pyrrole-2-carboxamido)propyl)-1H-1,2,3-triazol-4-yl)methyl)-
1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 3c[81].
Tri-Boc propargyl cyclam (47 mg, 0.088 mmol, 0.93 eq) and
methylpyrrole azide 2c (43 mg, 0.095 mmol, 1 eq) were reacted
together according to procedure B yielding a light yellow oil, which
was purified by flash column chromatography (ethyl acetate, RF
0.31) yielding 3c (73 mg, 78%) as a hygroscopic white gum; IR
(ATR) 3316, 2975, 2935, 1685 cm
21;
1HN M R(300 MHz,
CDCl3) d 8.07–8.55 (1H, br s, NH), 8.25–8.56 (2H, m, NH), 7.52
(1H, s, H
g), 6.70–6.90 (5H, m, Ar), 6.46–6.54 (1H, m, Ar), 6.02–
6.08 (1H, m, Ar), 4.39 (2H, m, H
h), 3.92 (3H, s, NCH3), 3.86 (3H, s,
NCH3), 3.82 (3H, s, NCH3), 3.62–3.80 (2H, m, H
j), 3.00–3.60
(14H,m,H
a,f), 2.52–2.65(2H,m,H
b), 2.30–2.50(2H, m, H
c), 2.10–
2.22 (2H, m, H
i), 1.80–1.95 (2H, m, H
d), 1.60–1.75 (2H, m, H
e),
1.42 (27H, s, 3 C(CH3)3) (Figure S11);
13CN M R(50.3 MHz,
CDCl3) d 162.1, 159.5, 159.0, 155.8, 128.3, 125.5, 123.0, 122.8,
121.7, 119.4, 119.2, 112.2, 107.3, 104.0, 103.6, 79.6, 44–50 (several
peaks), 36.7, 36.6, 30.0, 28.4 (Figure S12); MS (ESI) m/z 1012.8
(MNa
+, 100%); HRMS (ESI) calcd for C49H76N13O9
+ 990.58890
found 990.58835 (MH
+).
N-(3-(4-((1,4,8,11-Tetraazacyclotetradecan-1-yl)methyl)-1H-
1,2,3-triazol-1-yl)propyl)-1-methyl-1H-pyrrole-2-carboxamide
4a[81]. Monomethylpyrrole tri-Boc-protected cyclam 3a (0.55 g,
0.74 mmol 1 eq) was deprotected according to general procedure C
yielding 4a as a colourless oil. The product was purified by reverse
phase HPLC (2% CH3CN for 5 min, ramping to 60% over 40 min,
tR 20.7 min, Alltech-Altima C18 column (10 mm, 22 mm ID,
300 mm, 7 mL/min)) to yield compound 4a (0.24 g, 72%) as a
white foam; IR (ATR) 3272, 1634, 1546 cm
21;
1HN M R(200 MHz,
CDCl3)d7.51 (1H, s, H
g), 6.95 (1H, br s, NH), 6.48–6.55 (1H, m, Ar),
6.40–6.48 (1H, m, Ar), 5.80–5.90 (1H, m, Ar), 4.25 (2H, t, J 6.2 Hz,
H
h), 3.75 (3H, s, NCH3), 3.63 (2H, s, H
f), 3.16 (2H, m, H
j), 2.20–2.70
( 1 6 H ,m ,H
a,b,c), 1.87–2.10 (2H, m, H
i), 1.58–1.66 (2H, m, H
d), 1.60–
1.58 (2H, m, H
e) (Figure S13);
13CN M R(75.5 MHz, CDCl3) d
162.0, 143.8, 127.4, 125.1, 122.6, 111.7, 106.7, 54.1, 52.2, 50.4, 49.0,
48.8, 48.3, 47.6, 47.4, 46.8, 46.7, 36.2, 35.7, 30.1, 28.4, 25.7 (Figure
S14); MS (ESI) m/z 446.3 (MH
+,9 2 % ) ,HRMS (ESI) calcd for
C22H40N9O
+ 446.33558 found 446.33463 (MH
+).
N-(3-4-((1,4,8,11-Tetraazacyclotetradecan-1-yl)methyl)-1H-
1,2,3-trizol-1-yl)propyl)-1-methyl-4-(1-methyl-1H-pyrrole-2-
carboxamido)-1H-pyrrole-2-carboxamide 4b[81]. Bismeth-
ylpyrrole tri-Boc-protected cyclam 3b (278 mg, 0.32 mmol, 1 eq)
Figure 6. NMR spectroscopy assignment convention for
molecules containing cyclam.
doi:10.1371/journal.pone.0017446.g006
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compound 4b (180 mg, 99%) as a white gum without any
further purification; IR (ATR) 3288, 2935, 1641 cm
21;
1H
NMR (200 MHz, CDCl3) d 8.75 (1H, br s, NH), 7.65 (1H, s,
H
g), 7.32–7.36 (1H, m, Ar), 6.80–6.90 (2H, m, Ar), 6.70–7.76 (1H,
m, Ar), 6.57–6.68 (1H, m, Ar), 6.05–6.13 (1H, m, Ar), 4.40–4.50
(2H, m, H
h), 3.96 (3H, s, NCH3), 3.87 (3H, s, NCH3), 3.65–3.70
(2H, m, H
f), 3.36–3.43 (2H, m, H
j), 2.70–2.85 (12H, m, H
a), 2.64–
2.70 (2H, m, H
b), 2.50–2.63 (2H, m, H
c), 2.15–2.25 (2H, m, H
i),
1.80–1.90 (2H, m, H
d), 1.65–1.75 (2H, m, H
e) (Figure S15);
13C
NMR (50.3 MHz, CDCl3) 161.7, 159.4, 144.4, 128.0, 125.4,
123.0, 121.7, 119.1, 122.2, 106.9, 104.6 103.5, 54.5, 53.4, 53.1,
52.6, 50.2, 49.0, 48.4, 48.0, 47.2, 46.6, 36.4, 36.2, 29.4, 27.1, 25.0
(Figure S16); MS (ESI) m/z 568.3 (MH
+, 100%); HRMS (ESI)
calcd for C28H46N11O2
+ 568.38359 found 568.38305 (MH
+).
N-(3-(4-((1,4,8,11-Tetraazacyclotetradecan-1yl)methyl)-1H-
1,2,3-triazol-1-yl)propyl)-1-methyl-4-(1-methyl-4-(1-methyl-1H-
pyrrole-2-carboxamido)-1H-pyrrole-2-carboxamido)-1H-pyrr-
ole-2-carboxamide 4c[81]. Three-methylpyrrole tri-Boc-prot-
ected cyclam 3c (70 mg, 0.074 mmol, 1 eq) was deprotected
according to general procedure C yielding compound 4c (41 mg,
98%) as a pale yellow gum without any further purification; IR
(ATR) 3267, 2924, 1635 cm
21;
1HN M R(300 MHz, CDCl3) d
9.35 (2H, br s, 2 NH), 7.67 (1H, s, H
g), 7.51 (1H, br s, NH), 7.42–
7.47 (1H, m, Ar), 7.38–7.42 (1H, m, Ar), 7.05–7.16 (1H, m, Ar),
6.88–6.95 (1H, m, Ar), 6.81–6.88 (1H, m, Ar), 6.65–6.75 (1H, m,
Ar), 5.97–6.06 (1H, m, Ar), 5.00–5.85 (3H, br s, NH), 4.30–4.40
(2H, m, H
h), 3.93 (3H, s, NCH3), 3.88 (3H, s, NCH3), 3.81 (3H, s,
NCH3), 3.48–3.58 (2H, m, H
f), 3.27–3.40 (2H, m, H
j), 2.65–2.90
(12H, m, H
a), 2.51–2.62 (2H, m, H
b), 2.43–2.51 (2H, m, H
c), 2.10–
2.20 (2H, m, H
i), 1.72–1.80 (2H, m, H
d), 1.60–1.72 (2H, m, H
e)
(Figure S17);
13CN M R(75.5 MHz, CDCl3) d 162.0, 159.3, 158.9,
144.1, 128.1, 125.2, 123.3, 122.3, 122.2, 122.0, 121.8, 119.3, 118.8,
114.7, 112.8, 107.1, 103.6, 54.3, 50.0, 48.8, 48.5, 48.2, 47.7, 47.2,
46.1, 45.3, 36.9, 36.6, 36.5, 29.6, 29.2, 23.9 (Figure S18); MS (ESI)
m/z 690.3 (MH
+, 100%), HRMS (ESI) calcd for C34H52N13O3
+
690.43161 found 690.43152 (MH
+).
Complex 5a. Copper(II) chloride was complexed with 4a (2.0 mg,
4.50 mmol, 1.0 eq) according to general procedure D. The solution
was made up to 3 mL in methanol to a final concentration of
1.50 mM; UV-vis (MeOH) lmax=590 nm, e=414 M
21 cm
21;
MS (ESI) m/z 543.0 (C22H39
35ClCuN9O
+, 100%).
Complex 6a. Zinc(II) chloride was complexed with 4a (3.2 mg,
7.2 mmol, 1.0 eq) according to general procedure D. MS (ESI) m/
z 581.0 (multiplet).
1H NMR spectrum shown as Figure S19.
Complex 5b. Copper(II) chloride was complexed with 4b
(8.8 mg, 15.5 mmol, 1.0 eq) according to procedure D. The solution
was made up to 3 mL in methanol to a final concentration of
5.2 mM; UV-vis (MeOH) lmax=615 nm, e=113.8 M
21 cm
21;
MS (ESI) m/z 665.3 (C28H45
35ClCuN11O2
+, 100%), 667.3
(C28H45
37ClCuN11O2
+, 86%); HRMS (ESI) calcd for
C28H45
35ClCuN11O2
+ 665.27422 found 665.27305 ((M-Cl)
+), calcd
for C28H45
37ClCuN11O2
+ 667.27242 found 667.27176 ((M-Cl)
+).
Complex 6b. Zinc(II) chloride was complexed with 4b (2.7 mg,
4.8 mmol, 1.0 eq) according to procedure D. MS (ESI) m/z 583.3
(100%).
1H NMR spectrum shown as Figure S20.
Complex 5c. Copper(II) chloride was complexed with 4c
(0.94 mg, 1.36 mmol, 1.0 eq) according to procedure D. The
solution was made up to 3 mL in to a final concentration of
0.45 mM; UV-vis (MeOH) lmax=615 nm, e=162.7 M
21 cm
21;
IR (ATR) 3446, 2925, 1640, 1548, 1414, 1254, 1114, 742 cm
21;
MS (ESI) m/z 543.0 (C22H39
35ClCuN9O
+, 100%).
Complex 6c. Zinc(II) chloride was complexed with 4c (1.5 mg,
2.2 mmol, 1.0 eq) according to procedure D. MS (ESI) m/z 876.0
(96%), 875.1 (100%), 797.4 (93%), 795.3 (82%).
1H NMR
spectrum shown as Figure S21.
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Scheme S1 Synthetic Scheme for Supporting Information
Compounds.
(TIF)
Figure S1 CDCl3, 400 MHz
1H NMR spectrum of N-(3-
azidopropyl)-1-methylpyrrole-2-carboxamide (2a).
(TIFF)
Figure S2 CDCl3, 50.3 MHz
13C NMR spectrum of N-(3-
azidopropyl)-1-methylpyrrole-2-carboxamide (2a).
(TIFF)
Figure S3 CDCl3, 300 MHz
1H NMR spectrum of N-(3-
azidopropyl)-1-methyl-4-(1-methyl-1H-pyrrole-2-carboxamido)-1H-
pyrrole-2-carboxamide (2b).
(TIFF)
Figure S4 CDCl3, 75.5 MHz
13C NMR spectrum of N-(3-
azidopropyl)-1-methyl-4-(1-methyl-1H-pyrrole-2-carboxamido)-1H-
pyrrole-2-carboxamide (2b).
(TIFF)
Figure S5 CDCl3, 300 MHz
1H NMR spectrum of N-(3-
Azidopropyl)-1-methyl-4-(1-methyl-4-(1-methyl-1H-pyrrole-2-carb-
oxamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carboxamide
(2c).
(TIFF)
Figure S6 CDCl3, 75.5 MHz
13C NMR spectrum of N-(3-
azidopropyl)-1-methyl-4-(1-methyl-4-(1-methyl-1H-pyrrole-2-car-
boxamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carboxa-
mide (2c).
(TIFF)
Figure S7 CDCl3, 300 MHz
1H NMR spectrum of tri-tert-butyl
11-((1-(3-(1-methyl-1H-pyrrole-2-carboxamido)propyl)-1H-1,2,3-
triazol-4-yl)methyl)-1,4,8,11-tetraazacyclotetradecane-1,4,8-trica-
rboxylate (3a).
(TIFF)
Figure S8 CDCl3, 50.3 MHz
13H NMR spectrum of Tri-tert-
butyl 11-((1-(3-(1-methyl-1H-pyrrole-2-carboxamido)propyl)-1H-
1,2,3-triazol-4-yl)methyl)-1,4,8,11-tetraazacyclotetradecane-1,4,8-
tricarboxylate (3a).
(TIFF)
Figure S9 CDCl3, 300 MHz
1H NMR spectrum of tri-tert-butyl
11-((1-(3-(1-methyl-4-(1-methyl-1H-pyrrole-2-carboxamido)-1H-py-
rrole-2-carboxamido)propyl)-1H-1,2,3-triazol-4-yl)methyl)-1,4,8,11-
tetraazacyclotetradecane-1,4,8-tricarboxylate (3b).
(TIFF)
Figure S10 CDCl3, 50.3 MHz
13C NMR spectrum of tri-tert-
butyl 11-((1-(3-(1-methyl-4-(1-methyl-1H-pyrrole-2-carboxamido)-
1H-pyrrole-2-carboxamido)propyl)-1H-1,2,3-triazol-4-yl)methyl)-1,
4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate (3b).
(TIFF)
Figure S11 CDCl3, 300 MHz
1H NMR spectrum of tri-tert-
butyl 11-((1-(3-(1-methyl-4-(1-methyl-4-(1-methyl-1H-pyrrole-2-ca-
rboxamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carboxami-
do)propyl)-1H-1,2,3-triazol-4-yl)methyl)-1,4,8,11-tetraazacyclotetr-
adecane-1,4,8-tricarboxylate (3c).
(TIFF)
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13C NMR spectrum of tri-tert-
butyl 11-((1-(3-(1-methyl-4-(1-methyl-4-(1-methyl-1H-pyrrole-2-
carboxamido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carboxa-
mido)propyl)-1H-1,2,3-triazol-4-yl)methyl)-1,4,8,11-tetraazacyclo-
tetradecane-1,4,8-tricarboxylate (3c).
(TIFF)
Figure S13 CDCl3, 200 MHz
1H NMR spectrum of N-(3-(4-
((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)-1H-1,2,3-triazol-1-
yl)propyl)-1-methyl-1H-pyrrole-2-carboxamide (4a).
(TIFF)
Figure S14 CDCl3, 75.5 MHz
13C NMR spectrum of N-(3-(4-
((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)-1H-1,2,3-triazol-1-
yl)propyl)-1-methyl-1H-pyrrole-2-carboxamide (4a).
(TIFF)
Figure S15 CDCl3, 200 MHz
1H NMR spectrum of N-(3-4-
((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)-1H-1,2,3-trizol-1-yl)
propyl)-1-methyl-4-(1-methyl-1H-pyrrole-2-carboxamido)-1H-pyr-
role-2-carboxamide (4b).
(TIFF)
Figure S16 CDCl3, 50.3 MHz
13C NMR spectrum of N-(3-4-
((1,4,8,11-tetraazacyclotetradecan-1-yl)methyl)-1H-1,2,3-trizol-1-yl)
propyl)-1-methyl-4-(1-methyl-1H-pyrrole-2-carboxamido)-1H-pyr-
role-2-carboxamide (4b).
(TIFF)
Figure S17 CDCl3, 300 MHz
1H NMR spectrum of N-(3-(4-
((1,4,8,11-tetraazacyclotetradecan-1yl)methyl)-1H-1,2,3-triazol-1-yl)
propyl)-1-methyl-4-(1-methyl-4-(1-methyl-1H-pyrrole-2-carboxa-
mido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carboxamide
(4c).
(TIFF)
Figure S18 CDCl3, 75.5 MHz
13C NMR spectrum of N-(3-(4-
((1,4,8,11-tetraazacyclotetradecan-1yl)methyl)-1H-1,2,3-triazol-1-
yl)propyl)-1-methyl-4-(1-methyl-4-(1-methyl-1H-pyrrole-2-carboxa-
mido)-1H-pyrrole-2-carboxamido)-1H-pyrrole-2-carboxamide (4c).
(TIFF)
Figure S19 300 MHz, MeOD,
1H NMR spectrum of mono-
pyrrole zinc chloride cyclam complex (6a).
(TIFF)
Figure S20 300 MHz, MeOD,
1H NMR spectrum of di-pyrrole
zinc chloride cyclam complex (6b).
(TIFF)
Figure S21 300 MHz, MeOD,
1H NMR spectrum of tri-pyrrole
zinc chloride cyclam complex (6c).
(TIFF)
Figure S22 [125] Job plot for formation of complex between
copper(II) and ligand 4a.
(TIFF)
Figure S23 UV-vis spectrum for the titration of a solution of
CuCl2 with compound 4c in methanol (graphical representation of
raw data).
(TIFF)
Figure S24 Example ITC curve for GC-rich oligonucleotide
illustrating no observable binding; titration of 1000 mM 4c to
10 mM GC oligo (oligo II).
(TIFF)
Spreadsheet S1 Error calculations for Table 1.
(XLS)
Text S1 Procedures for preparation of known compounds, and
description of entropy error calculations.
(DOC)
Table S1 Effect of structural modifications of lexitropsins on
binding affinities for compound 4c vs. selected literature
compounds.
(DOC)
NMR Data S1 Raw NMR data files (.dx) for compounds 2–4
(
1H and
13C) and 6 (
1H).
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